(Q35728621)

9 August 2017

1 reference

title

Recent advancement in flavivirus vaccine development (English)

1 reference

9 August 2017

Gwong-Jen J Chang

1

1 reference

9 August 2017

Goro Kuno

series ordinal

2

1 reference

9 August 2017

David E Purdy

series ordinal

3

1 reference

9 August 2017

Brent S Davis

series ordinal

4

1 reference

9 August 2017

1 April 2004

1 reference

Expert Review of Vaccines

9 August 2017

1 reference

9 August 2017

3

1 reference

9 August 2017

2

1 reference

9 August 2017

199-220

1 reference

Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting

9 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Flavivirus genome organization, expression, and replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Epitope mapping of Japanese encephalitis virus envelope protein using monoclonal antibodies against an Indian strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Passive protection of mice, goats, and monkeys against Japanese encephalitis with monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-hu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Construction of intertypic chimeric dengue viruses by substitution of structural protein genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Development of new vaccines against dengue fever and Japanese encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

21 January 2018

West Nile virus vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Japanese encephalitis vaccines: moving away from the mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Antigen dependent adverse reactions and seroconversion of a tick-borne encephalitis vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

A live attenuated West Nile virus strain as a potential veterinary vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Smallpox: residual antibody after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Defective adenoviruses as novel vaccines for the Flaviviridae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self-replicating RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

A Japanese Encephalitis Virus Peptide Present on Johnson Grass Mosaic Virus-Like Particles Induces Virus-Neutralizing Antibodies and Protects Mice against Lethal Challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Incorporation of Tick-Borne Encephalitis Virus Replicons into Virus-Like Particles by a Packaging Cell Line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Infectious transcripts and cDNA clones of RNA viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

High fidelity of yellow fever virus RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Mimicking live flavivirus immunization with a noninfectious RNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Tick-Borne Langat/Mosquito-Borne Dengue Flavivirus Chimera, a Candidate Live Attenuated Vaccine for Protection against Disease Caused by Members of the Tick-Borne Encephalitis Virus Complex: Evaluation in Rhesus Monkeys and in Mosquitoes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Yellow fever vector live-virus vaccines: West Nile virus vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Evaluation of tick-borne encephalitis DNA vaccines in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Evaluation of the potency of BIKEN inactivated Japanese Encephalitis vaccine and DNA vaccines in an intracerebral Japanese Encephalitis virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Molecular aspects of TBE virus research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Development of a novel mouse model for dengue virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Acute Encephalitis, a Poliomyelitis-like Syndrome and Neurological Sequelae in a Hamster Model for Flavivirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Immunization with plasmid DNA encoding the envelope glycoprotein of Japanese Encephalitis virus confers significant protection against intracerebral viral challenge without inducing detectable antiviral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Serological evidence of West Nile virus, Usutu virus and Sindbis virus infection of birds in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Polio eradication: the OPV paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Immunization with Heterologous Flaviviruses Protective Against Fatal West Nile Encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Climate variability and transmission of Japanese encephalitis in eastern China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.2.199

Research on dengue during World War II

21 January 2018

1 reference

21 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.4269/AJTMH.1952.1.30

Identifiers

DOI

10.1586/14760584.3.2.199

1 reference

9 August 2017

1 reference